Literature DB >> 8964574

Clinical utility of sex hormone-binding globulin measurement.

M Pugeat1, J C Crave, J Tourniaire, M G Forest.   

Abstract

The high-affinity binding of the sex hormone-binding globulin (SHBG) for testosterone and to a lesser extent for estradiol influences the circulating levels of these sex steroid hormones, their biodisposal to target cells as well as their mutual balance. Although the regulation of SHBG is still not completely understood, in vitro studies performed with human hepatocarcinoma (Hep G2) cells have shown that estrogens and thyroxine stimulate SHBG secretion, by increasing the steady state of its mRNA concentrations. These observations are in good agreement with studies showing that SHBG levels increase during oral administration of estrogens as well as in patients with thyrotoxicosis. Interestingly, SHBG levels are normal in syndromes such as the abnormal transport of thyroid hormones and/or the syndrome of thyroid hormone resistance, which can be confused with thyrotoxicosis. By contrast, the effects of androgens are controversial. In many patients with hirsutism, SHBG concentrations are low and correlate negatively with both body mass index and fasting insulin levels. Because of the inhibitory effect of both insulin and insulin-like growth factor-1 on SHBG secretion by Hep G2 cells in vitro, it has been proposed that SHBG levels could be a marker of insulin resistance and/or hyperinsulinism in humans. Furthermore, an increased risk for either noninsulin-dependent diabetes and/or the overall mortality are associated with decreased SHBG levels in postmenopausal women. Finally, in men, SHBG levels are positively correlated with the concentration of high-density lipoprotein cholesterol. Therefore, the measurement of SHBG in clinical practice can be a useful diagnostic tool for: (1) correctly interpretating testosterone and estradiol serum concentrations; (2) investigating androgen-estrogen balance in gonadal and sexual dysfunctions; (3) assessing the peripheral effect of the hormones which regulate SHBG productions, and (4) evaluating insulin resistance and cardiovascular risk.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8964574     DOI: 10.1159/000184778

Source DB:  PubMed          Journal:  Horm Res        ISSN: 0301-0163


  17 in total

1.  TSH may not be a good marker for adequate thyroid hormone replacement therapy.

Authors:  Anton Staudenherz; Helmut Sinzinger
Journal:  Wien Klin Wochenschr       Date:  2006-06       Impact factor: 1.704

2.  Distinct metabolic surrogates predict basal and rebound GH secretion after glucose ingestion in men.

Authors:  Ali Iranmanesh; Donna Lawson; Johannes D Veldhuis
Journal:  J Clin Endocrinol Metab       Date:  2012-04-03       Impact factor: 5.958

3.  Association of rs6259 polymorphism with SHBG levels and Poly Cystic Ovary Syndrome in Indian population: a case control study.

Authors:  Richa Bhatnager; Alka Senwal; Smiti Nanda; Amita S Dang
Journal:  Mol Biol Rep       Date:  2019-02-04       Impact factor: 2.316

Review 4.  Understanding polycystic ovarian syndrome pathogenesis: an updated of its genetic aspects.

Authors:  A E Calogero; V Calabrò; M Catanuso; R A Condorelli; S La Vignera
Journal:  J Endocrinol Invest       Date:  2011-05-23       Impact factor: 4.256

5.  Cholesterol, endocrine and metabolic disturbances in sporadic anovulatory women with regular menstruation.

Authors:  Sunni L Mumford; Enrique F Schisterman; Anna Maria Siega-Riz; Audrey J Gaskins; Anne Z Steiner; Julie L Daniels; Andrew F Olshan; Mary L Hediger; Kathleen Hovey; Jean Wactawski-Wende; Maurizio Trevisan; Michael S Bloom
Journal:  Hum Reprod       Date:  2010-11-28       Impact factor: 6.918

Review 6.  The MCT8 thyroid hormone transporter and Allan-Herndon-Dudley syndrome.

Authors:  Charles E Schwartz; Roger E Stevenson
Journal:  Best Pract Res Clin Endocrinol Metab       Date:  2007-06       Impact factor: 4.690

7.  Genetics of polycystic ovary syndrome.

Authors:  N Prapas; A Karkanaki; I Prapas; I Kalogiannidis; I Katsikis; D Panidis
Journal:  Hippokratia       Date:  2009-10       Impact factor: 0.471

8.  Role of syndecan-3 polymorphisms in obesity and female hyperandrogenism.

Authors:  Andreas N Schüring; Friederike Lutz; Frank Tüttelmann; Jörg Gromoll; Ludwig Kiesel; Martin Götte
Journal:  J Mol Med (Berl)       Date:  2009-10-07       Impact factor: 4.599

Review 9.  Endocrine evaluation of erectile dysfunction.

Authors:  Andrea Sansone; Francesco Romanelli; Daniele Gianfrilli; Andrea Lenzi
Journal:  Endocrine       Date:  2014-04-06       Impact factor: 3.633

10.  The Genetic Basis of the Polycystic Ovary Syndrome: A Literature Review Including Discussion of PPAR-gamma.

Authors:  Ugur Unluturk; Ayla Harmanci; Cetin Kocaefe; Bulent O Yildiz
Journal:  PPAR Res       Date:  2007       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.